TearClear is an emerging global ophthalmic pharmaceutical company focused on disrupting the way current topical medications are delivered to the ocular surface. The company’s first in class pharmaceutical platform ensures patient safety and compliance by capturing preservatives prior to administration on to the ocular surface. TearClear’s lead candidates in glaucoma will pave the way for future indications across multiple programs in development.
Tear Film Innovation’s iLux treats Meibomian Gland Dysfunction by the application of light-based heat and compression under direct visualization.
Surface Pharmaceuticals’ branded drug candidates are being developed to address targeted segments of the Dry Eye Disease (DED) market.
Transforming the lens industry by being able to optimize a lens after implantation. RxSight has developed breakthrough intraocular lens technology for use in cataract and lens replacement surgery. Designed by a Nobel Prize winning scientist, RxSights’s Light Adjustable Lens (RxLAL) utilizes light to enable physicians to make office-based refractive adjustments after it has been implanted in the eye.
Orasis is an emerging ophthalmic pharmaceutical company with the goal of making near vision clear again. We are committed the Ophthalmology and Optometry segments because we know that presbyopia is ubiquitous. By virtue of our first in class formulation, Orasis is well positioned to be first line therapy in this emerging category by addressing a significant unmet need for patients.
Zepto, a precision pulse device that creates an accurate and reproducible capsulotomy that is quick, safe, and affordable.
Minimally invasive micro-interventional device to treat cataracts in safe and cost-effective manner without heat-generating vibrational energy or expensive electrically powered equipment.
CorneaGen’s mission is to provide the highest quality donor tissue, unparalleled customer service and superior products that transform how ophthalmologists treat and care for every person impacted by corneal disease.
The Economic Impact of the Ophthalmic Goods Manufacturing Industry on the Southern California Economy.
